Xencor Reports Positive Phase 1 XmAb942 Data and Preclinical XmAb412 Results, Advancing TL1A Franchise for Autoimmune Diseases
Summary
Xencor announced positive final Phase 1 data for XmAb942 and strong preclinical results for XmAb412, bolstering its TL1A pipeline for autoimmune diseases and supporting advanced clinical development.
Key Events
-
XmAb942 Phase 1 Final Results Positive
The Phase 1 study of XmAb942 in healthy participants showed it was safe and well-tolerated, with an estimated terminal half-life of 74.1 days supporting a 12-week maintenance dosing interval. The drug demonstrated favorable immunogenicity and is predicted to achieve superior TL1A inhibition compared to first-generation antibodies.
-
XmAb412 Preclinical Data Supports Novel Bispecific
Preclinical characterization of XmAb412, a TL1A x IL23p19 bispecific antibody using the novel XenLock™ platform, showed robust suppression of both inflammatory pathways and a predicted human half-life of 60-70 days. A first-in-human study is expected to begin in Q3 2026.
-
TL1A Franchise Positioned for Growth
Xencor is advancing its TL1A portfolio, positioning XmAb942 and XmAb412 as potentially best-in-class treatments for inflammatory bowel disease and other autoimmune diseases, with key clinical milestones expected through 2027.
Analysis
Xencor has reported final positive Phase 1 results for XmAb942, an anti-TL1A antibody, demonstrating a favorable safety profile, extended half-life supporting a 12-week dosing interval, and superior immunogenicity compared to first-generation competitors. This data significantly de-risks the ongoing Phase 2b XENITH-UC study for ulcerative colitis. Additionally, strong preclinical data for XmAb412, a novel TL1A x IL23p19 bispecific antibody utilizing the XenLock™ platform, positions it for a first-in-human study in Q3 2026. These updates reinforce Xencor's strategy to develop a best-in-class TL1A franchise, addressing a large and growing market in inflammatory bowel disease and other autoimmune conditions, which could drive future growth and partnerships.
At the time of this filing, XNCR was trading at $13.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $979.8M. The 52-week trading range was $6.92 to $18.69. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.